Shots:

• The EC has approved the Abevmy (100 & 400mg) for the treatment in metastatic colorectal carcinoma- metastatic breast cancer- NSCLC- glioblastoma- ovarian- cervical- and renal cancer as part of a specific regimen
• The approval follows CHMP’s positive opinion and is valid in all EU Member States as well as in the EEA countries Iceland- Liechtenstein- and Norway
• The approval will strengthen Biocon’s portfolio of biosimilars for cancer in the EU- which include biosimilar Trastuzumab and biosimilar Pegfilgrastim

  Ref: Biocon | Image: Medicircle